Selected variants of the steroid‐5‐alpha‐reductase isoforms SRD5A1 and SRD5A2 and the sex steroid hormone receptors ESR1, ESR2 and PGR: No association with female pattern hair loss identified

Redler, Silke; Tazi-Ahnini, Rachid; Drichel, Dmitriy; Birch, M.P.; Brockschmidt, Felix F.; Dobson, K.; Giehl, Kathrin; Refke, Melanie; Kluck, Nadine; Kruse, Roland; Lutz, G.; Wolff, Hans; Böhm, Markus; Becker, Tim; Nöthen, Markus M.; Betz, Regina C.; Messenger, A.G.

doi:10.1111/j.1600-0625.2012.01469.x

Cited by 23 publications

(13 citation statements)

References 40 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of aromates genes CYP19A1) (15) has been reported but not confirmed in a more recent study (16). In other studies there were no associations between steroid 5-alpha-reductase isoforms genes or sex steroid hormone receptors and FPHL (17). Neither there was association with melanocortin 4 receptor gene (18).…”

Section: Etiopathogenesismentioning

confidence: 75%

Female Pattern Hair Loss

Herskovitz

Tosti

2013

Int J Endocrinol Metab

View full text Add to dashboard Cite

Context:Female pattern hair loss (FPHL) also known as female androgenetic alopecia is a common condition afflicting millions of women that can be cosmetically disrupting. Prompt diagnosis and treatment are essential for obtaining optimal outcome.This review addresses the clinical presentation of female pattern hair loss, its differential diagnosis and treatment modalities.Evidence Acquisition:A) Diffuse thinning of the crown region with preservation of the frontal hairline (Ludwig’s type)B) The “Christmas tree pattern” where the thinning is wider in the frontal scalp giving the alopecic area a triangular shaped figure resembling a christmas tree.C) Thinning associated with bitemporal recession (Hamilton type).Generally, FPHL is not associated with elevated androgens.Less commonly females with FPHL may have other skin or general signs of hyperandrogenism such as hirsutism, acne, irregular menses, infertility, galactorrhea and insulin resistance. The most common endocrinological abnormality associated with FPHL is polycystic ovarian syndrome (PCOS).Results:The most important diseases to consider in the differential diagnosis of FPHL include Chronic Telogen Effluvium (CTE), Permanent Alopecia after Chemotherapy (PAC), Alopecia Areata Incognito (AAI) and Frontal Fibrosing Alopecia (FFA). This review describes criteria for distinguishing these conditions from FPHL.Conclusions:The only approved treatment for FPHL, which is 2% topical Minoxidil, should be applied at the dosage of 1ml twice day for a minimum period of 12 months. This review will discuss off-label alternative modalities of treatment including 5-alfa reductase inhibitors, antiandrogens, estrogens, prostaglandin analogs, lasers, light treatments and hair transplantation.

show abstract

Section: Etiopathogenesismentioning

confidence: 75%

Female Pattern Hair Loss

Herskovitz

Tosti

2013

Int J Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…Dear Editor , The aetiopathogenesis of female pattern hair loss (FPHL) is poorly understood. Although research has strongly implicated genetic factors in familial occurrence, no association finding for FPHL has yet been replicated . Consequently, no causal biological pathways can be suggested on the basis of currently available genetic findings.…”

Section: Association Analysis For Selected Markers At the Esr2 Gene Lmentioning

confidence: 99%

The oestrogen receptor 2 (ESR2) gene in female-pattern hair loss: replication of association with rs10137185 in German patients

et al. 2014

View full text Add to dashboard Cite

“…Recent studies have shown no involvement of the well-established locus on chromosome 20p11 in FPHL but have suggested that the androgen receptor/ectodysplasin A2 receptor (EDA2R) locus on the X chromosome confers susceptibility to early-onset FPHL [26]. In other studies, no association was found between steroid 5α-reductase isoform genes or sex steroid hormone receptors and FPHL [27]. Moreover, an Australian genome-wide association study suggested that the aromatase gene (CYP19A1) may contribute to FPHL, but this was not confirmed in another study [15,28].…”

Section: Discussionmentioning

confidence: 99%

Association of Single Nucleotide Polymorphisms in the CYP19A1 Gene with Female Pattern Hair Loss in a Chinese Population

Rui

Sheng

et al. 2015

Dermatology

View full text Add to dashboard Cite

Background: It has been suggested that the single nucleotide polymorphism (SNP) of the CYP19A1 gene encoding aromatase may affect the development of female pattern hair loss (FPHL). Objective: Our aim was to investigate the association of CYP19A1 gene SNPs with FPHL in a Chinese population. Methods: Two hundred Chinese Han patients with FPHL and 200 controls were enrolled into our study. SNaPshot technology was used to detect CYP19A1 gene candidate SNPs. Results: The allele frequencies and distributions of rs6493497 and rs7176005 were significantly different between FPHL and control subjects (p < 0.001 and p < 0.001 vs. p < 0.001 and p = 0.003). Conclusion: The rs6493497 and rs7176005 SNPs of the CYP19A1 gene may be genetic markers that influence the risk of FPHL in this Chinese population.

show abstract

Selected variants of the steroid‐5‐alpha‐reductase isoforms SRD5A1 and SRD5A2 and the sex steroid hormone receptors ESR1, ESR2 and PGR: No association with female pattern hair loss identified

Cited by 23 publications

References 40 publications

Female Pattern Hair Loss

Female Pattern Hair Loss

The oestrogen receptor 2 (ESR2) gene in female-pattern hair loss: replication of association with rs10137185 in German patients

Association of Single Nucleotide Polymorphisms in the CYP19A1 Gene with Female Pattern Hair Loss in a Chinese Population

Contact Info

Product

Resources

About